Neuroblastoma Care Advances Highlighted by Indian Hospital and UK Researchers

Neuroblastoma, the most common solid tumor in children under five, accounts for about 15% of pediatric cancer deaths. Survival exceeds 90% for low‑ and intermediate‑risk disease but remains below 60% for high‑risk cases, prompting the need for risk‑adapted treatment strategies that balance treatment intensity with organ preservation and long‑term quality of life.

A narrative review published on 6 January 2026 by specialists from the Royal Hospital for Children in Glasgow and the University of Liverpool outlines current diagnostic protocols—including urine catecholamine testing, MRI, MIBG imaging, bone‑marrow assessment and genetic profiling—and discusses the International Neuroblastoma Risk Group Staging System. The review details surgical controversies, emerging targeted therapies such as GD2‑directed antibodies, and the long‑term health needs of survivors.

Separately, the Basavatarakam Indo‑American Cancer Hospital & Research Institute in Hyderabad provides a comprehensive, multidisciplinary guide for parents, describing symptoms, diagnostic pathways and modern treatment options ranging from surgery and chemotherapy to stem‑cell transplantation, radiation and immunotherapy. The hospital’s team of pediatric oncologists, surgeons, radiologists and supportive‑care specialists emphasizes coordinated care throughout treatment and follow‑up.